Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Breast Cancer-Pipeline Review, H1 2015

Metastatic Breast Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Breast Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Breast Cancer-Pipeline Review, H1 2015', provides an overview of the Metastatic Breast Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Metastatic Breast Cancer Overview 8

Therapeutics Development 9

Metastatic Breast Cancer-Therapeutics under Development by Companies 11

Metastatic Breast Cancer-Therapeutics under Investigation by Universities/Institutes 21

Metastatic Breast Cancer-Pipeline Products Glance 23

Metastatic Breast Cancer-Products under Development by Companies 27

Metastatic Breast Cancer-Products under Investigation by Universities/Institutes 41

Metastatic Breast Cancer-Companies Involved in Therapeutics Development 43

Metastatic Breast Cancer-Therapeutics Assessment 155

Drug Profiles 180

Metastatic Breast Cancer-Recent Pipeline Updates 581

Metastatic Breast Cancer-Dormant Projects 817

Metastatic Breast Cancer-Discontinued Products 828

Metastatic Breast Cancer-Product Development Milestones 833

Appendix 843

List of Tables

Number of Products under Development for Metastatic Breast Cancer, H1 2015 31

Number of Products under Development for Metastatic Breast Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 34

Number of Products under Development by Companies, H1 2015 (Contd..1) 35

Number of Products under Development by Companies, H1 2015 (Contd..2) 36

Number of Products under Development by Companies, H1 2015 (Contd..3) 37

Number of Products under Development by Companies, H1 2015 (Contd..4) 38

Number of Products under Development by Companies, H1 2015 (Contd..5) 39

Number of Products under Development by Companies, H1 2015 (Contd..6) 40

Number of Products under Development by Companies, H1 2015 (Contd..7) 41

Number of Products under Development by Companies, H1 2015 (Contd..8) 42

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Development, H1 2015 47

Comparative Analysis by Unknown Stage Development, H1 2015 48

Products under Development by Companies, H1 2015 49

Products under Development by Companies, H1 2015 (Contd..1) 50

Products under Development by Companies, H1 2015 (Contd..2) 51

Products under Development by Companies, H1 2015 (Contd..3) 52

Products under Development by Companies, H1 2015 (Contd..4) 53

Products under Development by Companies, H1 2015 (Contd..5) 54

Products under Development by Companies, H1 2015 (Contd..6) 55

Products under Development by Companies, H1 2015 (Contd..7) 56

Products under Development by Companies, H1 2015 (Contd..8) 57

Products under Development by Companies, H1 2015 (Contd..9) 58

Products under Development by Companies, H1 2015 (Contd..10) 59

Products under Development by Companies, H1 2015 (Contd..11) 60

Products under Development by Companies, H1 2015 (Contd..12) 61

Products under Development by Companies, H1 2015 (Contd..13) 62

Products under Investigation by Universities/Institutes, H1 2015 63

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 64

Metastatic Breast Cancer-Pipeline by AbbVie Inc., H1 2015 65

Metastatic Breast Cancer-Pipeline by Advaxis, Inc., H1 2015 66

Metastatic Breast Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 67

Metastatic Breast Cancer-Pipeline by AlphaVax, Inc., H1 2015 68

Metastatic Breast Cancer-Pipeline by Amarna Therapeutics B.V., H1 2015 69

Metastatic Breast Cancer-Pipeline by Amgen Inc., H1 2015 70

Metastatic Breast Cancer-Pipeline by AngioGenex, Inc., H1 2015 71

Metastatic Breast Cancer-Pipeline by Aphios Corporation, H1 2015 72

Metastatic Breast Cancer-Pipeline by arGEN-X BV, H1 2015 73

Metastatic Breast Cancer-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 74

Metastatic Breast Cancer-Pipeline by AstraZeneca Plc, H1 2015 75

Metastatic Breast Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 76

Metastatic Breast Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 77

Metastatic Breast Cancer-Pipeline by Bayer AG, H1 2015 78

Metastatic Breast Cancer-Pipeline by BIOCAD, H1 2015 79

Metastatic Breast Cancer-Pipeline by Biocon Limited, H1 2015 80

Metastatic Breast Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 81

Metastatic Breast Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 82

Metastatic Breast Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 83

Metastatic Breast Cancer-Pipeline by CASI Pharmaceuticals Inc., H1 2015 84

Metastatic Breast Cancer-Pipeline by Celgene Corporation, H1 2015 85

Metastatic Breast Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 86

Metastatic Breast Cancer-Pipeline by Celltrion, Inc., H1 2015 87

Metastatic Breast Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 88

Metastatic Breast Cancer-Pipeline by Curadis GmbH, H1 2015 89

Metastatic Breast Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 90

Metastatic Breast Cancer-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 91

Metastatic Breast Cancer-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 92

Metastatic Breast Cancer-Pipeline by Eisai Co., Ltd., H1 2015 93

Metastatic Breast Cancer-Pipeline by Eli Lilly and Company, H1 2015 94

Metastatic Breast Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 95

Metastatic Breast Cancer-Pipeline by Etubics Corporation, H1 2015 96

Metastatic Breast Cancer-Pipeline by Eureka Therapeutics, Inc., H1 2015 97

Metastatic Breast Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 98

Metastatic Breast Cancer-Pipeline by Galileo Research s.r.l., H1 2015 99

Metastatic Breast Cancer-Pipeline by Genentech, Inc., H1 2015 100

Metastatic Breast Cancer-Pipeline by Genor BioPharma Co., Ltd., H1 2015 101

Metastatic Breast Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 102

Metastatic Breast Cancer-Pipeline by Glycotope GmbH, H1 2015 103

Metastatic Breast Cancer-Pipeline by GTx, Inc., H1 2015 104

Metastatic Breast Cancer-Pipeline by Hospira, Inc., H1 2015 105

Metastatic Breast Cancer-Pipeline by Immune Design Corp., H1 2015 106

Metastatic Breast Cancer-Pipeline by Immunomedics, Inc., H1 2015 107

Metastatic Breast Cancer-Pipeline by Immunovative Therapies, Ltd., H1 2015 108

Metastatic Breast Cancer-Pipeline by Immupharma Plc, H1 2015 109

Metastatic Breast Cancer-Pipeline by Imugene Limited, H1 2015 110

Metastatic Breast Cancer-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 111

Metastatic Breast Cancer-Pipeline by Incyte Corporation, H1 2015 112

Metastatic Breast Cancer-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 113

Metastatic Breast Cancer-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 114

Metastatic Breast Cancer-Pipeline by Johnson & Johnson, H1 2015 115

Metastatic Breast Cancer-Pipeline by Kadmon Corporation, LLC, H1 2015 116

Metastatic Breast Cancer-Pipeline by Kancera AB, H1 2015 117

Metastatic Breast Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 118

Metastatic Breast Cancer-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 119

Metastatic Breast Cancer-Pipeline by Mabion SA, H1 2015 120

Metastatic Breast Cancer-Pipeline by MacroGenics, Inc., H1 2015 121

Metastatic Breast Cancer-Pipeline by MandalMed, Inc., H1 2015 122

Metastatic Breast Cancer-Pipeline by Meabco A/S, H1 2015 123

Metastatic Breast Cancer-Pipeline by MedImmune, LLC, H1 2015 124

Metastatic Breast Cancer-Pipeline by Merck & Co., Inc., H1 2015 125

Metastatic Breast Cancer-Pipeline by Merck KGaA, H1 2015 126

Metastatic Breast Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 127

Metastatic Breast Cancer-Pipeline by Merus B.V., H1 2015 128

Metastatic Breast Cancer-Pipeline by MetaStat, Inc., H1 2015 129

Metastatic Breast Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 130

Metastatic Breast Cancer-Pipeline by Morphotek, Inc., H1 2015 131

Metastatic Breast Cancer-Pipeline by NanoCarrier Co., Ltd., H1 2015 132

Metastatic Breast Cancer-Pipeline by Natco Pharma Limited, H1 2015 133

Metastatic Breast Cancer-Pipeline by Nektar Therapeutics, H1 2015 134

Metastatic Breast Cancer-Pipeline by NewLink Genetics Corporation, H1 2015 135

Metastatic Breast Cancer-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 136

Metastatic Breast Cancer-Pipeline by Northwest Biotherapeutics, Inc., H1 2015 137

Metastatic Breast Cancer-Pipeline by Novartis AG, H1 2015 138

Metastatic Breast Cancer-Pipeline by Oasmia Pharmaceutical AB, H1 2015 139

Metastatic Breast Cancer-Pipeline by OBI Pharma, Inc., H1 2015 140

Metastatic Breast Cancer-Pipeline by Oncobiologics, Inc., H1 2015 141

Metastatic Breast Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 142

Metastatic Breast Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 143

Metastatic Breast Cancer-Pipeline by Oncothyreon Inc., H1 2015 144

Metastatic Breast Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 145

Metastatic Breast Cancer-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 146

Metastatic Breast Cancer-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 147

Metastatic Breast Cancer-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 148

Metastatic Breast Cancer-Pipeline by Pfizer Inc., H1 2015 149

Metastatic Breast Cancer-Pipeline by Pharma Mar, S.A., H1 2015 150

Metastatic Breast Cancer-Pipeline by Plexxikon Inc., H1 2015 151

Metastatic Breast Cancer-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 152

Metastatic Breast Cancer-Pipeline by Polyphor Ltd., H1 2015 153

Metastatic Breast Cancer-Pipeline by Prima BioMed Ltd., H1 2015 154

Metastatic Breast Cancer-Pipeline by Puma Biotechnology, Inc., H1 2015 155

Metastatic Breast Cancer-Pipeline by Radius Health, Inc., H1 2015 156

Metastatic Breast Cancer-Pipeline by Samyang Holdings Corporation, H1 2015 157

Metastatic Breast Cancer-Pipeline by Seattle Genetics, Inc., H1 2015 158

Metastatic Breast Cancer-Pipeline by Sorrento Therapeutics, Inc., H1 2015 159

Metastatic Breast Cancer-Pipeline by Starpharma Holdings Limited, H1 2015 160

Metastatic Breast Cancer-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 161

Metastatic Breast Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 162

Metastatic Breast Cancer-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 163

Metastatic Breast Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 164

Metastatic Breast Cancer-Pipeline by Theracrine, Inc., H1 2015 165

Metastatic Breast Cancer-Pipeline by Tiziana Life Sciences Plc, H1 2015 166

Metastatic Breast Cancer-Pipeline by Transgene Biotek Limited, H1 2015 167

Metastatic Breast Cancer-Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015 168

Metastatic Breast Cancer-Pipeline by Verastem, Inc., H1 2015 169

Metastatic Breast Cancer-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170

Metastatic Breast Cancer-Pipeline by VioQuest Pharmaceuticals, Inc., H1 2015 171

Metastatic Breast Cancer-Pipeline by Wilex AG, H1 2015 172

Metastatic Breast Cancer-Pipeline by WntResearch AB, H1 2015 173

Metastatic Breast Cancer-Pipeline by ZIOPHARM Oncology, Inc., H1 2015 174

Metastatic Breast Cancer-Pipeline by Zymeworks Inc., H1 2015 175

Metastatic Breast Cancer-Pipeline by Zyngenia, Inc., H1 2015 176

Assessment by Monotherapy Products, H1 2015 177

Assessment by Combination Products, H1 2015 178

Number of Products by Stage and Target, H1 2015 180

Number of Products by Stage and Mechanism of Action, H1 2015 191

Number of Products by Stage and Route of Administration, H1 2015 199

Number of Products by Stage and Molecule Type, H1 2015 201

Metastatic Breast Cancer Therapeutics-Recent Pipeline Updates, H1 2015 603

Metastatic Breast Cancer-Dormant Projects, H1 2015 839

Metastatic Breast Cancer-Dormant Projects (Contd..1), H1 2015 840

Metastatic Breast Cancer-Dormant Projects (Contd..2), H1 2015 841

Metastatic Breast Cancer-Dormant Projects (Contd..3), H1 2015 842

Metastatic Breast Cancer-Dormant Projects (Contd..4), H1 2015 843

Metastatic Breast Cancer-Dormant Projects (Contd..5), H1 2015 844

Metastatic Breast Cancer-Dormant Projects (Contd..6), H1 2015 845

Metastatic Breast Cancer-Dormant Projects (Contd..7), H1 2015 846

Metastatic Breast Cancer-Dormant Projects (Contd..8), H1 2015 847

Metastatic Breast Cancer-Dormant Projects (Contd..9), H1 2015 848

Metastatic Breast Cancer-Dormant Projects (Contd..10), H1 2015 849

Metastatic Breast Cancer-Discontinued Products, H1 2015 850

Metastatic Breast Cancer-Discontinued Products (Contd..1), H1 2015 851

Metastatic Breast Cancer-Discontinued Products (Contd..2), H1 2015 852

Metastatic Breast Cancer-Discontinued Products (Contd..3), H1 2015 853

Metastatic Breast Cancer-Discontinued Products (Contd..4), H1 2015 854

List of Figures

Number of Products under Development for Metastatic Breast Cancer, H1 2015 31

Number of Products under Development for Metastatic Breast Cancer-Comparative Analysis, H1 2015 32

Number of Products under Development by Companies, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Products, H1 2015 47

Assessment by Monotherapy Products, H1 2015 177

Assessment by Combination Products, H1 2015 178

Number of Products by Top 10 Targets, H1 2015 179

Number of Products by Stage and Top 10 Targets, H1 2015 179

Number of Products by Top 10 Mechanism of Actions, H1 2015 190

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 190

Number of Products by Top 10 Routes of Administration, H1 2015 198

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 198

Number of Products by Top 10 Molecule Types, H1 2015 200

Number of Products by Stage and Top 10 Molecule Types, H1 2015 200

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Advaxis, Inc.

Advenchen Laboratories, LLC

AlphaVax, Inc.

Amarna Therapeutics B.V.

Amgen Inc.

AngioGenex, Inc.

Aphios Corporation

arGEN-X BV

Aslan Pharmaceuticals Pte. Ltd.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bavarian Nordic A/S

Bayer AG

BIOCAD

Biocon Limited

BioMarin Pharmaceutical Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CASI Pharmaceuticals Inc.

Celgene Corporation

Celldex Therapeutics, Inc.

Celltrion, Inc.

Corcept Therapeutics Incorporated

Curadis GmbH

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

Dompe Farmaceutici S.p.A.

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Etubics Corporation

Eureka Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Galileo Research s.r.l.

Genentech, Inc.

Genor BioPharma Co., Ltd.

GlaxoSmithKline Plc

Glycotope GmbH

GTx, Inc.

Hospira, Inc.

Immune Design Corp.

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Immupharma Plc

Imugene Limited

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

Intas Pharmaceuticals Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Johnson & Johnson

Kadmon Corporation, LLC

Kancera AB

Karyopharm Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Mabion SA

MacroGenics, Inc.

MandalMed, Inc.

Meabco A/S

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Merus B.V.

MetaStat, Inc.

Millennium Pharmaceuticals, Inc.

Morphotek, Inc.

NanoCarrier Co., Ltd.

Natco Pharma Limited

Nektar Therapeutics

NewLink Genetics Corporation

Nippon Kayaku Co., Ltd.

Northwest Biotherapeutics, Inc.

Novartis AG

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Oncobiologics, Inc.

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Oncothyreon Inc.

Ono Pharmaceutical Co., Ltd.

Panacea Pharmaceuticals, Inc.

Paras Biopharmaceuticals Finland Oy

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Polyphor Ltd.

Prima BioMed Ltd.

Puma Biotechnology, Inc.

Radius Health, Inc.

Samyang Holdings Corporation

Seattle Genetics, Inc.

Sorrento Therapeutics, Inc.

Starpharma Holdings Limited

Sumitomo Dainippon Pharma Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Theracrine, Inc.

Tiziana Life Sciences Plc

Transgene Biotek Limited

Vaxil Bio Therapeutics Ltd.

Verastem, Inc.

Vertex Pharmaceuticals Incorporated

VioQuest Pharmaceuticals, Inc.

Wilex AG

WntResearch AB

ZIOPHARM Oncology, Inc.

Zymeworks Inc.

Zyngenia, Inc.

Metastatic Breast Cancer Therapeutic Products under Development, Key Players in Metastatic Breast Cancer Therapeutics, Metastatic Breast Cancer Pipeline Overview, Metastatic Breast Cancer Pipeline, Metastatic Breast Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com